| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 4.8MM | +5% |
| Gross Profit | 2.4MM | -4% |
| Cost Of Revenue | 2.5MM | +15% |
| Operating Income | -3.4MM | +18% |
| Operating Expenses | 5.8MM | +8% |
| Net Income | -3.2MM | -4% |
| R&D | 1.3MM | +13% |
| G&A | 2.5MM | +16% |
| Marketing | 2MM | -3% |
| Interest Expense | 50K | -22% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2024 after the close of trading on Monday, April 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webca
SAN RAFAEL, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding (“PDAC”) contractor for the Centers for Medicare & Medicaid Services (“CMS”) has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal, which took effect on April 1, 2024. As previou
Ekso Bionics Holdings ( NASDAQ:EKSO ) Full Year 2023 Results Key Financial Results Revenue: US$18.3m (up 42% from FY...
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2023 Earnings Call Transcript March 4, 2024 Ekso Bionics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.11. EKSO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and […]
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -100% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and Accomplishments Achieved record revenue of $18.3 million for the 2023 full year, an increase of 42% year-over-yearSold a total of 151 EksoHeal
SAN RAFAEL, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2023 after the close of trading on Monday, March 4, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
With the business potentially at an important milestone, we thought we'd take a closer look at Ekso Bionics Holdings...